NeoMatrix Breast Health Solutions

NeoMatrix Breast Health Solutions

Excerpted from the site:
"Based in Irvine, Calif., NeoMatrix develops innovative devices that allow women and their doctors to promote optimal breast health. The company's premier product, the HALO™ Breast Pap Test, is the only fully automated, noninvasive breast disease screening device designed for use in the Primary Care setting as part of an annual well-woman visit."

"The HALO™ Breast Pap Test gives doctors and patients a new method to monitor breast cancer risk, quickly and easily. The fact is, all women are at risk for developing breast cancer. In the US we spend $3 billion annually on breast cancer screening, yet more than 70% of lumps are discovered during self-exams. Unfortunately, by the time a woman can actually feel the lump, the disease is no longer in its earliest, most treatable stage."

About NeoMatrix, LLC:

In their own words; NeoMatrix "Based in Irvine, Calif., NeoMatrix© develops innovative devices that allow women and their Ob-Gyns to promote optimal breast health. The company's premier product, the HALO Breast Pap Test System, is the first fully automated, noninvasive breast disease screening device designed for use in the primary care office setting. The System has been FDA cleared for the collection of nipple aspirate fluid for cytological evaluation for the determination and/or differentiation of normal versus pre-malignant versus malignant cells. For further information, visit www.neomatrix.com."


In a press release on September 05, 2007, NeoMatrix announced "additional funding for breakthrough breast cancer screening test".

"IRVINE, Calif. – Sept. 5, 2007 – NeoMatrix, developer of the HALO™ Breast Pap Test, the first automatic, noninvasive test designed to identify breast cancer risk, announced today that the company has closed a Series C round of equity financing. The financing will enable an expanded market release of the HALO System, which is designed to test asymptomatic women for the presence of atypical ductal hyperplasia (ADH), a known biomarker that can be a precursor to breast cancer. ADH is often found in the breast years earlier than a lesion might be found on a mammogram or a self exam, facilitating early follow-up and treatment or chemoprevention measures."

And if you are looking to contact NeoMatrix:

NeoMatrix
16 Technology Drive, Suite 118
Irvine, CA 92618

Telephone: (949) 753-7844
Toll-free: (800) 600-2613
FAX: (949) 753-7845

To contact us via e-mail: info@neomatrix.com